03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
|
|
- Geoffrey Dawson
- 6 years ago
- Views:
Transcription
1 CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no financial disclosures. TO OPERATE OR NOT THAT IS THE QUESTION What is the modern benefit of performing carotid endarterectomy for patients with high grade asymptomatic disease? 1
2 THE CRUX OF THE ISSUE Data from ACAS, NASCET and the VA Study were collected nearly 25 years ago. Things have changed Statins Clopidogrel Modern maximal medical therapy has reduced risk of stroke from asymptomatic carotid stenosis to rates equivalent to that obtained from CEA (Abbott et al 2009). Lifetime risk of stroke in a 65-year-old male has decreased from 19.5% in the 1970s to 14.5% today THE REAL ISSUE HISTORICAL PERSPECTIVE OF RCTS VA Study ACAS ACST Year Inclusion criteria Asymptomatic > 50% stenosis Asymptomatic > 60% stenosis Asymptomatic (mainly) > 60% stenosis Comparison CEA + aspirin vs. medical treatment alone CEA + aspirin vs. Aspirin CEA + medical tx vs. medical and risk factor modification tx alone (or until CEA necessary) 80 % on Statins in later years of trial Results Ipsi neuro events 8% for CEA, 20.6% for medical tx, BUT no difference in all strokes and deaths between two groups 5 year risk of ipsi stroke and perioperative stroke or death was 5.1% for CEA, 11% for medical tx 5 year risk of stroke or death was 6.4% for CEA vs 11.8% for medical tx The winner CEA CEA CEA 2
3 IN A NEW ERA, WHAT IS THE BENEFIT? What is the impact of modern maximal medical therapy? Does this impact stroke risk reduction in ACAS? What are the costs of medical treatment vs CAS/CEA? MODERN MAXIMAL MEDICAL THERAPY MAXIMAL MEDICAL THERAPY Smoking cessation Anti-hypertensives Diabetes control Anti-platelets Statins 3
4 MAXIMAL MEDICAL THERAPY Statins 1987 lovastatin (Atorvastatin, Fluvastatin, Pravastatin, Rosuvastatin, simvastatin, Pitavastatin) $29 billion in global sales in 2012 Plavix 1998 clopidogrel $9 billion in global sales in 2010 IMPACT OF THESE DRUGS: STATIN CLOPIDOGREL Cholesterol Treatment Trialists Collaboration Reducing LDL by 1 mmol/l decreases the incidence of major vascular events (nonfatal myocardial infarction, coronary death, any stroke, or coronary revascularization procedure) by ~1/5 Further reductions in LDL cholesterol with more intensive statin regimens yielded further reductions in risk CAPRIE Trial - reduction of cardiovascular events in patients with recent stroke, MI, or peripheral artery disease Expanded indications to include ACS, NSTEMI, STEMI, coronary stent BUT CAPRIE Trial No difference in clopidogrel vs aspirin in > 6000 with recent ischemic stroke Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial clopidogrel plus aspirin = aspirin alone in preventing vascular events in patients with a prior stroke, TIA, or other cardiovascular disease or in patients with high risk for cardiovascular disease. 4
5 AND STATINS FOR STROKE PREVENTION: DISAPPOINTMENT AND HOPE The number of strokes prevented per 1000 patients treated for 5 years in patients with CHD is 9 for statins, compared with 17.3 for antiplatelet agents. Statins do not prevent recurrent stroke in patients with prior stroke Statins may increase the risk of hemorrhagic stroke Amarenco & Tonkin Circulation. 2004;109:III-44 III-49. META-ANALYSIS OF 9 MAJOR LONG-TERM STATIN TRIALS PATIENTS WITH KNOWN CHD OR CONSIDERED AT INCREASED RISK 4.3 % (1501 of patients) risk of stroke in control group 3.4 % (1215 of patients) risk of stroke with statin therapy 21% relative risk reduction in stroke 0.9% absolute risk reduction (9 strokes prevented per 1000 patients treated for 5 years). By comparison, meta analyses have shown that, in similar patients with known CHD 17 strokes per 1000 patients prevented with Ramipril treatment for 5 years 17.3 strokes per 1000 patients prevented with antiplatelet agents (45 strokes prevented per 1000 patients treated for 5 years in patients with prior stroke) HOW DOES MAXIMAL MEDICAL THERAPY INFLUENCE STROKE RISK IN ACAS? 5
6 MEDICAL (NONSURGICAL) INTERVENTION ALONE IS NOW BEST FOR PREVENTION OF STROKE ASSOCIATED WITH ASYMPTOMATIC SEVERE CAROTID STENOSIS: RESULTS OF A SYSTEMATIC REVIEW AND ANALYSIS 1. Investigate temporal changes in reported stroke rate among patients with ACAS receiving MMT alone 2. Compare above stroke rate rates with those of patients who received CEA in major randomized surgical trials 3. Compare stroke-prevention cost effectiveness of medical intervention alone with MMT plus CEA. Abbott et al. Stroke ABBOTT, STROKE 2009 Meta-review of studies of severe (> 50%) asymptomatic carotid stenosis Found significant decrease in stroke rate from 1980s to 2000s. Abbott et al. Stroke
7 ABBOTT, STROKE 2009 Author notes that no systematic analysis of reported stroke rate associated with isolated medical management of ACAS has been performed. One of the author s arguments is that the low peri-operative risk associated with CEA in these trials is not comparable to the risk in the community at large. The flip side to this argument is that in order to benefit from the reduced stroke risk associated with MMT, patients must be compliant. In the community at large, is compliance equivalent to that of trial patients? THE EFFECT OF MEDICAL TREATMENTS ON STROKE RISK IN ASYMPTOMATIC CAROTID STENOSIS ACES data 477 patients with ACES Followed Q6mos for 2 yrs King et al King et al
8 THE WORLD AT LARGE or at least a nation SVS VASCULAR REGISTRY REVIEW 2015 Normal Risk patients Age < 80 Absence of clinically significant cardiac disease Absence of severe pulmonary disease Absence of contralateral carotid occlusion Absence of contralateral laryngeal nerve palsy No history of radical neck surgery or radiation to neck No recurrent stenosis SVS REGISTRY 8
9 MODERN DATA ACST-1 10 YEAR FOLLOW UP DATA (2010) Stroke rates were lower in those on lipid-lowering therapy, the absolute difference in the stroke incidence rate produced by allocation to immediate CEA was not as great (0 7 vs 1 3% per year [p<0 0001] for those currently on lipid-lowering therapy, and 1 8 vs 3 3% per year [p<0 0001] for those not The event rates in patients on lipid-lowering therapy suggest somewhat lower perioperative risks and lower absolute benefits, but still with a significant reduction in net risk at year 10. In patients with effective antihypertensive, antithrombotic, and lipid-lowering therapy and with little likelihood of death from other causes within 10 years, the absolute 10-year stroke reduction would be about 5%. If so, the number needed to treat to avoid one stroke would be about 20. Allowance for non-compliance might reduce this number to about 15. MODERN DATA Aggressive Medical Treatment Evaluation for Asymptomatic Carotid Artery Stenosis (AMTEC) Study Group Russia has higher rate of stroke and death than Western countries 55 patients with % asymptomatic stenosis randomized MMT and 31 CEA + MMT MMT defined as Aspirin Statin Anti-hypertensives 9
10 AMTEC Nonfatal stroke and death (1 endpoint) Nonfatal stroke, carotid revascularization, and death (2 endpoint) Major adverse cardiovascular events* Cumulative rate at 3.3 years CEA (%) MMT (%) Nonfatal stroke Death *Death, nonfatal myocardial infarction, nonfatal stroke, carotid revascularization, and coronary revascularization. CONRAD ET AL 900 carotid arteries in 794 patients 87.1% were on a statin throughout the study low-density lipoprotein cholesterol level was always normal (<100 mg/dl) in 37.8% and accordingly, 241 (30.3%) had OMT The 5-year freedom from plaque progression was 61.2% vs 62.1% with no benefit from OMT vs the control group. 11.3% patients developed INS during follow-up (58% of these were strokes) Statins were protective Conclusions: At the 5-year of follow-up, OMT failed to prevent carotid disease progression or development of ipsilateral symptoms in 45% of patients with ACAS. J Vasc Surg 2013;58: CONRAD ONE YEAR LATER 126 asymptomatic but severely stenotic (> 70%) carotid arteries 86% on statin 24.6% developed ipsi neuro event during mean of 27 month follow up Statins not protective against ipsi neuro events or death 10
11 ASYMPTOMATIC CAROTID STENOSIS: RISK OF PROGRESSION AND DEVELOPMENT OF SYMPTOMS Retrospective review of 214 consecutive patients 97% statins 95% anti-hypertensives 99% aspirin 68% progression of stenosis 21% develop ipsilateral symptoms in long term follow up Mean of 6 years to development of symptoms Risk factors for symptom development Degree of stenosis at diagnosis Intracranial stenosis Plaque ulceration Silent infarction Prior history of TIA/stroke Cerebrovasc Dis 2015;40: WHAT IS GOING ON? DEFINITION OF SEVERE CAROTID STENOSIS Abbott et al : > 50% ACAS: > 60% by either angio or duplex VA: >50% by angio SVS guidelines 60% Common practice 70% 11
12 SMOKING Although the world-wide prevalence of tobacco use has decreased, the total number of smokers has increased due to population growth. Certain countries have rates of tobacco use >50% in men (i.e Russia). LENGTH OF FOLLOW UP Cerebrovasc Dis 2015;40: IS THERE A SELECTION BIAS? Medical compliance Smoking cessation 12
13 WHAT ABOUT COST? INDEX HOSPITALIZATION COSTS CAS VS CEA (CREST TRIAL) CAS CEA Difference P Value Procedure $6782 ± 1412 $5743 ± 1370 $1039 < Post procedure $6759 ± 4815 $7122 ± $ Physician fees $1514 ± 446 $1951 ± $437 < Total index hospitalization $15,055 ± 5539 $14,816 ± 7709 $ NUMBER NEEDED TO TREAT 9 strokes prevented per 1000 patients treated with statins for 5 years NNT = 111 ACST-1 data reported needed to treat patients to prevent one stroke. NNT = 20 13
14 COST COMPARISON Statins Lipitor $4000 / year x 5 years = 20,000 x 111 patients = CEA / CAS $15, 000 per procedure x 20 procedures = $ 2,220,000 to prevent 1 stroke $ 300,000 prevent 1 stroke CLOSING THOUGHTS SPACE-2 Designed as three armed randomized trial to compare best medical therapy alone, best medical therapy plus CAS and best medical therapy plus CEA Low recruitment has halted the study (Jan 2015) Plans to analyze and report out available data later this year. 14
15 CREST-2 Randomized trial of patients with asymptomatic carotid stenosis 70% Medical treatment alone versus medical treatment and endarterectomy Medical treatment alone versus medical treatment and stenting Recruiting 2480 patients in US and Canada COGNITIVE EFFECTS OF CEA Patients with asymptomatic severe carotid stenosis perform poorer on tests of cognitive function than controls. Carotid revascularization improves memory and attention within the first 6 postoperative months in patients with >80% ACAS. Kougias, P et al. J Vasc Surg 2015;62: REFERENCES Amarenco P & Tonkin AM. Circulation. Statins for Stroke Prevention Disappointment and Hope 2004;109:III-44 III-49. Benavente O, et al. Carotid endarterectomy for asymptomatic carotid stenosis:a metaanalysis. BMJ 1998;317: Bhatt DL, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354: Bonati LH, et al. Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 2015; 385: 529 Brothers, TE et al. Contemporary results of carotid endarterectomy in normal-risk patients from the Society for Vascular Surgery Vascular Registry. J Vasc Surg 2015;62: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348: Conrad, MF et al. Progression of asymptomatic carotid stenosis despite optimal medical therapy. J Vasc Surg 2013;58: Conrad, MF et al. The natural history of asymptomatic severe carotid artery stenosis. J Vasc Surg 2014;60: Diener HC, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 2004;364: Endarterectomy for asymptomatic carotid stenosis. JAMA 1995;273: Halliday A, et al. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:
16 REFERENCES Hobson, RW et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. NEJM 1993;328: King, A et al. The Effect of Medical Treatments on Stroke Risk in Asymptomatic Carotid Stenosis. Stroke. 2013;44: Kolos, I et al. Modern medical treatment with or without carotid endarterectomy for severe asymptomatic carotid atherosclerosis. J Vasc Surg 2015;62: Kougias, P et al. Comparison of domain-specific cognitive function after carotid endarterectomy and stenting. J Vasc Surg 2015;62: Martinic-Popovic, I et al. Advanced Asymptomatic Carotid Disease and Cognitive Impairment: An Understated Link? Stroke Research and Treatment Volume 2012, Nicolaides AN, et al. Effect of image normalization on carotid plaque classification and the risk of ipsilateral hemispheric ischemic events: results from the asymptomatic carotid stenosis and risk of stroke study. Vascular 2005; 13: Rijbroek, A et al. Asymptomatic Carotid Artery Stenosis: Past, Present and Future. Eur Neurol 2006;56: Singh TD, et al. Asymptomatic Carotid Stenosis: Risk of Progression and Development of Symptoms. Cerebrovasc Dis 2015;40: Vilain, KR et al. Costs and Cost-Effectiveness of Carotid Stenting versus Endarterectomy for Patients at Standard Surgical Risk: Results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Stroke. 2012; 43: Yadav, JS et al. Protected Carotid-Artery Stenting versus Endarterectomy in High-Risk Patients. N Engl J Med 2004;351:
Carotid Artery Stenosis
Evidence-Based Approach to Carotid Artery Stenosis Seong-Wook Park, MD Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Carotid Artery Stenosis Carotid
More informationDisclosures. State of the Art Management of Carotid Stenosis. NIH funding for clinical trials Consultant for Scientia Vascular and Medtronic
State of the Art Management of Carotid Stenosis Mark R. Harrigan, MD UAB Stroke Center Professor of Neurosurgery, Neurology, and Radiology University of Alabama, Birmingham Disclosures NIH funding for
More informationHow to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention
How to Choose Between Carotid Stenting and Carotid Endarterectomy for Stroke Prevention Christopher J. White MD, MSCAI Chief of Medical Services, Professor and Chairman of Medicine Ochsner Medical Center
More informationCarotid Artery Stenting
Carotid Artery Stenting Woong Chol Kang M.D. Gil Medical Center, Gachon University of Medicine and Science, Incheon, Korea Carotid Stenosis and Stroke ~25% of stroke is due to carotid disease, the reminder
More informationTreatment Considerations for Carotid Artery Stenosis. Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery
Treatment Considerations for Carotid Artery Stenosis Danielle Zielinski, RN, MSN, ACNP Rush University Neurosurgery 4.29.2016 There is no actual or potential conflict of interest in regards to this presentation
More informationCarotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective)
Carotid Endarterectomy vs. Carotid artery Stenting (Surgeon Perspective) T-Woei Tan, MD, FACS, RPVI Assistant Professor of Surgery Vascular and Endovascular Surgery Louisiana State University Health -
More informationMORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million life insurance
MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS October 17, 2012 AAIM Triennial Conference, San Diego Robert Lund, MD What Is The Risk? 73 year old NS right-handed male applicant for $1
More informationSlide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure
Slide 1 The Treatment of Intracranial Stenosis Helmi Lutsep, MD Vice Chair and Dixon Term Professor, Department of Neurology, Oregon Health & Science University Chief of Neurology, VA Portland Health Care
More informationMORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS. 73 year old NS right-handed male applicant for $1 Million Life Insurance
MORTALITY AND MORBIDITY RISK FROM CAROTID ARTERY ATHEROSCLEROSIS October 17, 2012 AAIM Triennial Conference, San Diego Robert Lund, MD What Is The Risk? 73 year old NS right-handed male applicant for $1
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationCardioLucca2014. Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee. Fabrizio Tomai
CardioLucca2014 Fare luce sulla scelta ottimale del trattamento nella rivascolarizzazione delle stenosi carotidee Fabrizio Tomai European Hospital e Aurelia Hospital Roma Treatment of Carotid Artery Disease
More informationThe Great Swedish Debate. Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund
The Great Swedish Debate Håkan Pärsson Department Vascular Surgery Helsingborgs Lasarett, University Lund My Disclosures Trying to bribe the moderators What do my patients expect? Balanced information
More informationAsymptomatic Carotid Stenosis To Do or Not To Do
Asymptomatic Carotid Stenosis To Do or Not To Do October 22, 2016 Neurosciences: Updates and Controversies Andrew C. MacDougall, MD Advocate Medical Group Advocate Lutheran General Hospital Principle
More informationNew Trials in Progress: ACT 1. Jon Matsumura, MD Cannes, France June 28, 2008
New Trials in Progress: ACT 1 Jon Matsumura, MD Cannes, France June 28, 2008 Faculty Disclosure I disclose the following financial relationships: Consultant, CAS training director, and/or research grants
More informationCarotid Artery Stenting Versus
Carotid Artery Stenting Versus Carotid Endarterectomy Seong-Wook Park, MD, PhD, FACC,, Seoul, Korea Stroke & Carotid artery stenosis Stroke & Carotid artery stenosis Cerebrovascular disease is one of the
More informationCarotid Artery Revascularization: Current Strategies. Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014
Carotid Artery Revascularization: Current Strategies Shonda Banegas, D.O. Vascular Surgery Carondelet Heart and Vascular Institute September 6, 2014 Disclosures None 1 Stroke in 2014 Stroke kills almost
More informationICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria
Safety Results NOT for The following slides were presented to the Investigators Meeting on 22/05/09 and most of them were also presented at the European Stroke Conference on 27/05/09 They are NOT for in
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationStroke prevention in asymptomatic carotid stenosis. ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ
Stroke prevention in asymptomatic carotid stenosis ΛΙΛΛΗΣ ΛΕΩΝΙΔΑΣ Καρδιολόγος Επιστημονικός Συνεργάτης Α Καρδιολογικής Κλινικής ΑΠΘ ΠΓΝΘ ΑΧΕΠΑ Σεμινάρια Ομάδων Εργασίας Ελληνικής Καρδιολογικής Εταιρείας
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSurgical Treatment of Carotid Disease
Department of Cardiothoracic & Vascular Surgery McGovern Medical School / The University of Texas Health Science Center at Houston Surgical Treatment of Carotid Disease The Old, the New, and the Future
More informationUpdate on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2
Update on the only remaining Carotid Multicenter Randomised International Trial in the World:ACST-2 Alison Halliday MD Professor of Vascular Surgery University of Oxford Disclosure Statement of Financial
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationPost-op Carotid Complications A Nursing Perspective of What to Watch Out for
Post-op Carotid Complications A Nursing Perspective of What to Watch Out for By Kariss Peterson, ARNP Swedish Medical Center Inpatient Neurology Team 1 Post-op Carotid Management Objectives Review the
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationApproach to the Patient with Carotid Artery Disease
Approach to the Patient with Carotid Artery Disease Michael R. Jaff, DO, FACP, FACC Director, Vascular Medicine Massachusetts General Hospital Boston, Massachusetts Conflict of Interest Statement Within
More informationThe Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered?
TCT 2009 San Francisco, California September 22, 2009 The Effectiveness of Medical Therapy for Severe Carotid Stenosis in Reducing Large-Vessel Embolic Stroke: Open Question or Question Answered? Michael
More informationBest Medical Therapy for asymptomatic carotid disease
Best Medical Therapy for asymptomatic carotid disease Richard Bulbulia Consultant Vascular Surgeon and Co-PI ACST-2 MRC Population Health Research Unit CTSU, Nuffield Department of Population Health University
More informationHow good is current best medical therapy (BMT) for stroke prevention in patients with asymptomatic carotid stenosis?
How good is current best medical therapy (BMT) for stroke prevention in patients with asymptomatic carotid stenosis? Dorothee Saur Department of Neurology University of Leipzig Disclosure for Dorothee
More informationCarotid Artery Disease How the Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient
Carotid Artery Disease How the 2014-2015 Data Will Influence Management The Symptomatic vs. the Asymptomatic Patient Christopher J. White, MD, MSCAI, FACC, FAHA, FESC Professor and Chair of Medicine Ochsner
More informationBULgarian Carotid Artery Stenting versus Surgery Study (BULCASSS): Randomized single center trial
BULgarian Carotid Artery Stenting versus Surgery Study (): Randomized single center trial Ivo Petrov, M. Konteva, H. Dimitrov, K. Kichukov Tokuda Hospital Sofia Cardiology Department Background Carotid
More informationThe argument against revascularization for asymptomatic carotid stenosis
The argument against revascularization for asymptomatic carotid stenosis Seemant Chaturvedi, MD, FAHA, FAAN Professor of Clinical Neurology Vice-Chair for VA Programs Univ. of Miami Miller School of Medicine
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCAROTID STENTING A 2009 UPDATE. Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital
CAROTID STENTING A 2009 UPDATE Hoang Duong, MD Director of Interventional Neuroradiology Memorial Regional Hospital TREATMENT FOR CAROTID STENOSIS Best medical management Antiplatelet therapy Antihypertensive
More informationMEET Θ symptomatic patients. K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany
MEET Θ 2006 Why I stent asymptomatic and symptomatic patients K. Mathias Department of Radiology Teaching Hospital of Dortmund - Germany Evidence for treating symptomatic patients symptomatic patients
More informationContemporary Management of Carotid Disease What We Know So Far
Contemporary Management of Carotid Disease What We Know So Far Ammar Safar, MD, FSCAI, FACC, FACP, RPVI Interventional Cardiology & Endovascular Medicine Disclosers NONE Epidemiology 80 % of stroke are
More informationFast-track CEA: a 3-year experience
Fast-track CEA: a 3-year experience Giorgio L. Poletto, MD Milano, Italy 6th ACST-2 Collaborators Meeting, Palau de Congresos, Valencia. 24th and 25th September 2018. Stroke prevention Primary prevention:
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationPeter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI
Peter A. Soukas, M.D., FACC, FSVM, FSCAI, RPVI Director, Peripheral Vascular Interventional Laboratory Director, Vascular & Endovascular Medicine Fellowship Program Assistant Professor of Medicine The
More informationCurrent Medical Therapy for
STROKE Current Medical Therapy for Stroke Prevention and Treatment Endovascular Today engages lipid expert Richard Milani, MD, and stroke expert Roekchai Tulyapronchote, MD, in a rapid-fire Q&A session.
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationUPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE?
UPMC HAMOT CAROTID ARTERY DISEASE WHERE DO WE GO FROM HERE? Richard W. Petrella M.D. FACP,FACC,FASCI DEPARTMENT CHAIRMAN CVM&S UPMC HAMOT MEDICAL CENTER 1 LEARNING OBJECTIVES REVIEW THE RISK FACTORS FOR
More informationWhich Patients Are Good Candidates for Carotid Artery Stenting or Carotid Endarterectomy
13 th Annual Angioplasty Summit TCT Asia Pacific Seoul, Korea April 24, 2008 Which Patients Are Good Candidates for Carotid Artery Stenting or Carotid Endarterectomy Michael R. Jaff, DO, FACP, FACC Associate
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationESC Heart & Brain Workshop
ESC Heart & Brain Workshop The role of vascular surgeon in stroke prevention Barbara Rantner, MD, PhD, Department of Vascular Surgery, Medical University Innsbruck, Innsbruck, Austria Supported by Bayer,
More informationCLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationCarotid Artery Stenting (CAS) Pathophysiology. Technical Considerations. Plaque characteristics: relevant concepts. CAS and CEA
Carotid Artery Stenting (CAS) Carotid Artery Stenting for Stroke Risk Reduction Matthew A. Corriere MD, MS, RPVI Assistant Professor of Surgery Department of Vascular and Endovascular Surgery Rationale:
More informationOpen heart surgery or carotid endarterectomy. Which procedure should be done first?
Open heart surgery or carotid endarterectomy. Which procedure should be done first? Pedro Pinto Sousa 1, Gabriela Teixeira 2, João Gonçalves 2 ; Luís Vouga 1, Rui Almeida 2 ; Pedro Sá Pinto 2 1 Centro
More informationCarotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO
Carotid Artery Disease and What s Pertinent JOSEPH A PAULISIN DO Goal of treatment of carotid disease Identify those at risk of developing symptoms Prevent patients at risk from developing symptoms Prevent
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationDESCRIPTION: Percent of asymptomatic patients undergoing CEA who are discharged to home no later than post-operative day #2
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
More informationCo chce/čeká neurochirug od anesteziologa během karotické endarterektomie?
XXV. kongres České společnosti anesteziologie, resuscitace a intenzivní medicíny, Praha 3.-5.10. 2018 Co chce/čeká neurochirug od anesteziologa během karotické endarterektomie? Hejčl A., Orlický M., Sameš
More informationCarotid Artery Stent: Is it ready for prime time?
2010 CATH LAB SYMPOSIUM Carotid Artery Stent: Is it ready for prime time? Luis F. Tami, MD, FACC, FSCAI Interventional Cardiology and Vascular Medicine Memorial Regional Hospital August 2010 CAE and CAS
More informationMy Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position
LINC 2016 Leipzig, Jan 26-29, 2016 My Latest Take on RCT Data: When is CEA or CAS the Best Option? The Interventional Position Horst Sievert, Iris Grunwald CardioVasculäres Centrum Frankfurt - CVC, Frankfurt
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More information2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
Measure #260: Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Patient Safety
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationCAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough
Todd W GenslerMD April 28, 2018 CAROTID DEBATE High-Grade Asymptomatic Disease Should Be Repaired Selectively; Medical Management is NOT Enough DISCLOSURES I have no financial disclosures Presenter name
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationSTROKE UPDATE ANTHEA PARRY MAY 2010
STROKE UPDATE ANTHEA PARRY MAY 2010 Delivery of stroke care Clinical presentations Management Health Care for London plan 8 HASU (hyperacute) units 20 stroke units TIA services Hyperacute stroke units
More informationCurrent Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS. Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford
Current Status and Perspectives of ACST-2, CREST-2, ECST-2 and ACTRIS Richard Bulbulia Co-Principal Investigator ACST-2 University of Oxford Two BIG questions in carotid research Question #1 Should we
More information2015 Update in Diagnosis and Management of Stroke
2015 Update in Diagnosis and Management of Stroke S. Andrew Josephson MD Carmen Castro Franceschi and Gladyne K. Mitchell Neurohospitalist Distinguished Professor Senior Executive Vice Chair, Department
More informationCLINICAL TIMELINE EVA-3S CREST ICSS SPACE SAPPHIRE
Normal Risk Symptomatic Patients: Ongoing Debate CAS vs CEA John R. Laird, MD Professor of Medicine Medical Director of the Vascular Center University of California, Davis CLINICAL TIMELINE Randomized
More information2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Outcome
Measure #344: Rate of Carotid Artery Stenting (CAS) for Asymptomatic Patients, Without Major Complications (Discharged to Home by Post-Operative Day #2) National Quality Strategy Domain: Effective Clinical
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationVivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine
Vivek R. Deshmukh, MD Director, Cerebrovascular and Endovascular Neurosurgery Chairman, Department of Neurosurgery Providence Brain and Spine Institute The Oregon Clinic Disclosure I declare that neither
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More informationPeripheral Arterial Occlusive Disease- The Challenge in patients with diabetes
Peripheral Arterial Occlusive Disease- The Challenge in patients with diabetes Ashok Handa Reader in Surgery and Consultant Surgeon Nuffield Department of Surgery University of Oxford Introduction Vascular
More informationESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH
ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME: INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH AUTHORS: Marta Ponte 1, RICARDO
More informationThe recent joint guidelines[1] of the European Society of Cardiology and European
Supplementary material Musiałek P, Grunwald IQ. How asymptomatic is asymptomatic carotid stenosis? Resolving confusion(s) and confusions yet to be resolved. Pol Arch Intern Med. 2017. doi: Please note
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationWill guidelines and clinical practice for asymptomatic stenosis change in the near future?
Will guidelines and clinical practice for asymptomatic stenosis change in the near future? M Storck, MD, PhD Director Dept. Vascular and Thoracic Surgery Klinikum Karlsruhe Academic Teaching Hospital,
More informationTCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS
TCAR: TransCarotid Artery Revascularization Angela A. Kokkosis, MD, RPVI, FACS Assistant Professor of Surgery Director of Carotid Interventions Division of Vascular & Endovascular Surgery Stony Brook University
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationOctogenarians Must Be Treated With CAS
Some Octogenarians Must Be Treated With CAS LN Hopkins, MD E Levy MD, Adnan Siddiqui,, MD, PhD Rod Samuelson MD J Mocco MD LN Hopkins, MD Potential Conflicts Consultant & research support: Boston Scientific,
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationGuidelines for Management of Ischaemic Stroke The European Stroke Organization - ESO - Executive Committee and Writing Committee
Guidelines for Management of Ischaemic Stroke 2008 The European Stroke Organization - ESO - Executive Committee and Writing Committee ESO Writing Committee Prevention Co-Chairs: Phil Bath, Nottingham,
More informationStroke secondary prevention. Gill Cluckie Stroke Nurse Consultant St. George s Hospital
Stroke secondary prevention Gill Cluckie Stroke Nurse Consultant St. George s Hospital Stroke recurrence The risk of recurrent stroke is greatest after first stroke 2 3% of survivors of a first stroke
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationClinical Decision Making: Hyperacute Management of Symptomatic Carotid Artery Disease
Clinical Decision Making: Hyperacute Management of Symptomatic Carotid Artery Disease Tarvinder Singh, MS, MD Neurohospitalist Swedish Neuroscience Institute 1 Objectives Definition Why the urgency? Evidence/Guidelines
More informationI want Medical Therapy for my ASYMPTOMATIC patients with Carotid Disease
I want Medical Therapy for my ASYMPTOMATIC patients with Carotid Disease Alonso Collar, M.D. F.A.C.S. Chief of Surgery Chair Cardiovascular Surgery Sparrow Hospital Lansing, MI I want Medical Therapy for
More informationPrevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano
Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationHow Duplex Ultrasound Screening Can Lead to Overuse of Carotid Interventions. No Disclosures. Prevalence >70% Asymptomatic ICA Stenosis*
How Duplex Ultrasound Screening Can Lead to Overuse of Carotid Interventions Gregory L. Moneta, M.D. Chief, Division of Vascular Surgery Department of Surgery Knight Cardiovascular Institute Oregon Health
More informationSession : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION
Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More information